Benzinga · Aug 7, 2026
Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and lowers the price target from $36 to $34.
IN
NASDAQ · INVA
Innoviva, Inc.
Healthcare · Biotechnology
$20.77
Down-$0.20 (-0.95%)
Updated Sep 1, 2026, 7:03 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.33B
- P/E ratio
- 33.55
- Dividend yield
- 0.00%
- 52-week range
- $20.20 – $24.45
- Volume
- 877.39K
- Avg. volume
- 812.23K
Price performance
INVA price history
1M range · 21 trading sessions · Daily adjusted prices
INVA closed at $20.77 after 21 trading sessions, up 0.00% for the selected period.
- Last close
- $20.77
- Period change
- +0.00%
- Period low
- $20.51
- Period high
- $21.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $20.97 | $21.05 | $20.68 | $20.77 | 877.39K |
| Aug 28, 2026 | $20.96 | $21.07 | $20.80 | $20.97 | 527.01K |
| Aug 27, 2026 | $20.99 | $21.095 | $20.8601 | $20.96 | 488.06K |
| Aug 26, 2026 | $21.15 | $21.33 | $20.84 | $21.24 | 693.03K |
| Aug 25, 2026 | $21.10 | $21.24 | $20.93 | $21.17 | 412.69K |
| Aug 24, 2026 | $21.07 | $21.10 | $20.89 | $21.03 | 510.3K |
| Aug 21, 2026 | $21.01 | $21.23 | $20.895 | $21.07 | 499.38K |
| Aug 20, 2026 | $21.34 | $21.41 | $20.87 | $21.00 | 796.48K |
| Aug 19, 2026 | $21.45 | $21.6962 | $21.36 | $21.48 | 505.51K |
| Aug 18, 2026 | $21.24 | $21.46 | $21.205 | $21.25 | 628.82K |
| Aug 17, 2026 | $21.04 | $21.20 | $20.84 | $20.96 | 618.01K |
| Aug 14, 2026 | $20.72 | $21.215 | $20.68 | $21.19 | 448.81K |
| Aug 13, 2026 | $21.00 | $21.0101 | $20.59 | $20.75 | 527.24K |
| Aug 12, 2026 | $20.69 | $21.12 | $20.62 | $20.81 | 595.87K |
| Aug 11, 2026 | $20.68 | $20.86 | $20.54 | $20.75 | 596.04K |
| Aug 10, 2026 | $20.42 | $20.82 | $20.39 | $20.68 | 877.65K |
| Aug 7, 2026 | $20.93 | $20.96 | $20.20 | $20.51 | 1.14M |
| Aug 6, 2026 | $21.13 | $22.09 | $20.7436 | $21.11 | 1.31M |
| Aug 5, 2026 | $21.01 | $21.13 | $20.49 | $20.51 | 702.94K |
| Aug 4, 2026 | $20.635 | $20.88 | $20.50 | $20.86 | 564.65K |
| Aug 3, 2026 | $20.97 | $21.155 | $20.60 | $20.77 | 799.11K |
Latest INVA news
The latest Smart Investors Daily articles mentioning INVA.
Stock researchCompany · Overview
INVA research
Overview
Company profile and research snapshot.
Company profile
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $26.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 22, 2026 | BTIG | Buy | — |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | — |
| May 26, 2026 | BTIG | Buy | — |
| May 7, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 5, 2026
Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate
Innoviva (NASDAQ:INVA) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $0.40 by 385 percent. This is a 248.05 percent decrease over earnings of $0.77 per share from the same
ChartMill · Jul 28, 2026
Innoviva (INVA): Affordable Growth Stock at a Reasonable Valuation
Article missing. Unable to generate summary.
ChartMill · Jul 7, 2026
Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong Fundamentals
Discover Innoviva (NASDAQ:INVA), a strong value stock with a Valuation score of 9/10, solid Profitability and Health ratings, and excellent growth prospects. A deep value opportunity with a P/E ratio of just 5.83.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
